NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP
Madrigal Pharmaceuticals, Inc. MDGL
17 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$958.4M
▲ 432.1% vs FY2024
EPS · FY25
$-12.85
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-42.5%
Net margin · FY25
-30.1%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 958.4M
Revenue, FY2025 · full 17-year series below
Revenue
Net income
The company lost 30 cents on every revenue dollar this year.
Per share
USD -12.85
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-42.5%
Return on equity, FY2025
ROE
Operating margin-31.3%
Net margin-30.1%
Return on assets-25.0%
Each USD of equity lost 42 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.02B
Shares outstanding, FY2025
Change, 5 years+47.3%
Change, 10 years—
The share count grew 47% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 1.3B
total assets, end of FY2025
Total assetsUSD 1.3B
EquityUSD 602.7M
CashUSD 198.7M
Gross debtUSD 339.9M
Net debtUSD 141.2M
Current ratio4.01×
Net debt stands at 23% of equity.
History
17 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
Revenue $B
1.0
0.2
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
·
·
·
0.0
·
·
·
Operating income $B
−0.3
−0.5
−0.4
−0.3
−0.2
−0.2
−0.1
−0.0
−0.0
−0.0
−0.0
−0.1
−0.1
−0.1
−0.0
−0.0
0.1
EBITDA $B
−0.3
−0.5
−0.4
−0.3
−0.2
−0.2
−0.1
−0.0
−0.0
−0.0
−0.0
−0.1
−0.1
−0.1
−0.0
−0.0
0.1
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
·
·
·
·
·
·
·
·
Net income $B
−0.3
−0.5
−0.4
−0.3
−0.2
−0.2
−0.1
−0.0
−0.0
−0.0
−0.0
−0.1
−0.1
−0.1
−0.0
−0.0
0.1
EPS, diluted $
−12.85
−21.90
−19.99
−17.23
−14.63
−13.09
−5.45
−2.22
−2.54
−5.07
−40.03
−0.87
−1.27
−1.06
−1.00
−0.93
2.32
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−42.5
−80.3
−124.0
−150.1
−110.9
−61.6
−18.8
−10.0
−28.5
·
·
−2453.9
−145.3
−139.8
−247.7
−154.9
317.5
Shares out B
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.01
0.01
0.00
0.11
0.09
0.07
0.05
0.04
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
49 of 49
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed